On August 24, 2025, Innovent Biologics, Inc. ("Innovent") announced its operations in SAN FRANCISCO and SUZHOU, China. Innovent, listed as HKEX: 01801, is dedicated to producing top-notch medicines in oncology, cardiovascular, and metabolic diseases.